Chromadex Current Deferred Revenue vs Net Debt Analysis
CDXC Stock | USD 7.59 0.13 1.74% |
Chromadex Corp financial indicator trend analysis is way more than just evaluating Chromadex Corp prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Chromadex Corp is a good investment. Please check the relationship between Chromadex Corp Current Deferred Revenue and its Net Debt accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Chromadex Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. For information on how to trade Chromadex Stock refer to our How to Trade Chromadex Stock guide.
Current Deferred Revenue vs Net Debt
Current Deferred Revenue vs Net Debt Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Chromadex Corp Current Deferred Revenue account and Net Debt. At this time, the significance of the direction appears to have no relationship.
The correlation between Chromadex Corp's Current Deferred Revenue and Net Debt is 0.09. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Net Debt in the same time period over historical financial statements of Chromadex Corp, assuming nothing else is changed. The correlation between historical values of Chromadex Corp's Current Deferred Revenue and Net Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of Chromadex Corp are associated (or correlated) with its Net Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Debt has no effect on the direction of Current Deferred Revenue i.e., Chromadex Corp's Current Deferred Revenue and Net Debt go up and down completely randomly.
Correlation Coefficient | 0.09 |
Relationship Direction | Positive |
Relationship Strength | Insignificant |
Current Deferred Revenue
Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.Net Debt
The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.Most indicators from Chromadex Corp's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Chromadex Corp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Chromadex Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. For information on how to trade Chromadex Stock refer to our How to Trade Chromadex Stock guide.At present, Chromadex Corp's Enterprise Value is projected to increase significantly based on the last few years of reporting.
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 55K | 3K | 3.5K | 3.3K | Depreciation And Amortization | 1.6M | 1.9M | 1.7M | 863.7K |
Chromadex Corp fundamental ratios Correlations
Click cells to compare fundamentals
Chromadex Corp Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Chromadex Corp fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 40.2M | 38.4M | 57.8M | 54.1M | 55.0M | 28.4M | |
Short Long Term Debt Total | 1.7M | 1.6M | 4.7M | 4.3M | 3.3M | 1.7M | |
Total Current Liabilities | 15.1M | 16.5M | 17.6M | 17.9M | 20.6M | 21.7M | |
Total Stockholder Equity | 20.4M | 16.4M | 31.7M | 28.7M | 28.5M | 15.9M | |
Net Debt | (17.1M) | (14.9M) | (23.3M) | (16.0M) | (23.9M) | (22.7M) | |
Retained Earnings | (121.9M) | (141.8M) | (169.0M) | (185.5M) | (190.5M) | (180.9M) | |
Accounts Payable | 9.6M | 9.4M | 10.4M | 9.7M | 10.2M | 5.6M | |
Cash | 18.8M | 16.5M | 28.0M | 20.2M | 27.3M | 28.7M | |
Non Current Assets Total | 6.7M | 6.1M | 8.9M | 7.5M | 5.4M | 4.3M | |
Non Currrent Assets Other | 762K | 625K | 723K | 497K | 383K | 354.2K | |
Cash And Short Term Investments | 18.8M | 16.5M | 28.0M | 20.2M | 27.3M | 28.7M | |
Net Receivables | 2.2M | 2.7M | 5.2M | 8.5M | 5.2M | 3.2M | |
Common Stock Total Equity | 60K | 62K | 68K | 74K | 85.1K | 69.4K | |
Common Stock Shares Outstanding | 57.1M | 61.1M | 67.2M | 69.7M | 75.0M | 43.1M | |
Liabilities And Stockholders Equity | 40.2M | 38.4M | 57.8M | 54.1M | 55.0M | 28.4M | |
Non Current Liabilities Total | 4.7M | 5.5M | 8.5M | 7.5M | 5.9M | 6.2M | |
Inventory | 11.5M | 11.7M | 13.6M | 14.7M | 14.5M | 7.4M | |
Other Stockholder Equity | 142.3M | 158.2M | 200.6M | 214.1M | 218.8M | 229.8M | |
Total Liab | 19.8M | 21.9M | 26.1M | 25.4M | 26.5M | 27.8M | |
Property Plant And Equipment Gross | 4.7M | 4.4M | 7.4M | 6.3M | 9.9M | 10.4M | |
Total Current Assets | 33.5M | 32.2M | 48.9M | 46.6M | 49.5M | 52.0M | |
Accumulated Other Comprehensive Income | (2.1M) | 0.0 | (3K) | (2K) | (4K) | (4.2K) | |
Intangible Assets | 1.3M | 1.1M | 857K | 671K | 510K | 694.8K | |
Common Stock | 60K | 62K | 68K | 74K | 75K | 70.5K | |
Other Current Liab | 4.4M | 5.5M | 5.4M | 5.9M | 8.1M | 8.5M | |
Property Plant And Equipment Net | 4.7M | 4.4M | 7.4M | 6.3M | 4.5M | 3.2M | |
Current Deferred Revenue | 169K | 278K | 161K | 157K | 195K | 263.8K | |
Other Current Assets | 996K | 1.3M | 3.7M | 3.0M | 2.5M | 2.6M | |
Short Term Debt | 853K | 1.2M | 1.1M | 1.4M | 1.4M | 1.5M | |
Other Liab | 3.9M | 4.4M | 4.3M | 4.0M | 4.5M | 4.8M | |
Net Tangible Assets | 19.1M | 16.4M | 30.9M | 28.0M | 32.2M | 18.4M | |
Other Assets | 762K | 625K | 723K | 497K | 571.6K | 600.1K | |
Retained Earnings Total Equity | (121.9M) | (141.8M) | (169.0M) | (185.5M) | (166.9M) | (158.6M) | |
Property Plant Equipment | 4.7M | 3.2M | 7.4M | 6.3M | 7.3M | 7.6M | |
Capital Surpluse | 142.3M | 158.2M | 200.6M | 214.1M | 246.2M | 258.5M | |
Capital Lease Obligations | 1.7M | 1.6M | 4.7M | 4.3M | 3.3M | 1.7M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Chromadex Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Chromadex Corp's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Chromadex Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Chromadex Corp Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Chromadex Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. For information on how to trade Chromadex Stock refer to our How to Trade Chromadex Stock guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Chromadex Corp. If investors know Chromadex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Chromadex Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.02 | Revenue Per Share 1.215 | Quarterly Revenue Growth 0.312 | Return On Assets 0.0051 | Return On Equity 0.0482 |
The market value of Chromadex Corp is measured differently than its book value, which is the value of Chromadex that is recorded on the company's balance sheet. Investors also form their own opinion of Chromadex Corp's value that differs from its market value or its book value, called intrinsic value, which is Chromadex Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Chromadex Corp's market value can be influenced by many factors that don't directly affect Chromadex Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Chromadex Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Chromadex Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Chromadex Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.